Device Trial Radar · NCT05813704
Coronary Crossing System in Patients With Coronary Chronic Total Occlusions
Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
159
Actual
Start
Nov 7, 2023
Primary completion
Jul 19, 2024
Study completion Aug 19, 2024
Sponsor
- Lead sponsor
- Shanghai MicroPort Rhythm MedTech Co., Ltd.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Shanghai Zhongshan Hospital; Xiamen Cardiovascular Hospital, Xiamen University; Shanghai Baoshan District Wusong Central Hospital; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; The First Affiliated Hospital of Nanchang University; First Affiliated Hospital Xi'an Jiaotong University; First Affiliated Hospital of Wenzhou Medical University; Tianjin First Central Hospital; The Affiliated Hospital Of Southwest Medical University; Hebei General Hospital; First Affiliated Hospital of the Chinese People's Liberation Army Naval Medical University; LanZhou University; Nanfang Hospital, Southern Medical University; The Second Affiliated Hospital of Dalian Medical University; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine; West China Hospital
- First posted
- Apr 14, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective and multicenter clinical investigation aiming to evaluate the safety and effectiveness of coronary crossing system for the treatment of patients with coronary chronic total occlusions.
Conditions
- Chronic Total Occlusion of Coronary Artery
Interventions
Coronary Crossing System of Shanghai MicroPort RhythmDevice
The mechanical vibration generated by the Coronary Crossing System through the piezoelectric effect is amplified and transmitted to the distal end of the guidewire to achieve high-frequency vibration at the tip of the guidewire, and then achieve efficient and safe penetration of the fibrous cap of the CTO.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Device successTime frame: Baseline procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongshan Hospital of Fudan University
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.